Hyperparathyroidism 2

Common Name(s)

Hyperparathyroidism 2

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hyperparathyroidism 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Hyperparathyroidism 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Hyperparathyroidism 2" returned 4 free, full-text research articles on human participants. First 3 results:

Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study.
 

Author(s): Neal Mittman, Brinda Desiraju, Kevin B Meyer, Jyoti Chattopadhyay, Morrell M Avram

Journal: Kidney Int. Suppl.. 2010 Aug;(117):S33-6.

 

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease. The management of SHPT commonly involves vitamin D, either calcitriol or newer analogs (paricalcitol or doxercalciferol), along with dietary phosphorus restriction and phosphate binding agents. ...

Last Updated: 30 Jul 2010

Go To URL
The association of primary hyperparathyroidism and primary ovarian failure: a de novo t(X; 2) (q22p13) reciprocal translocation.
 

Author(s): Gul Bano, Sahar Mansour, Stephen Nussey

Journal: Eur. J. Endocrinol.. 2008 Feb;158(2):261-3.

 

A 40-year-old female presented with primary amenorrhoea at 17 years of age. She was tall at 98th centile for height with eunuchoidal body habitus. Her breast development was Tanner stage 3, pubic and axillary hair Tanner stage 4 with normal external genitalia. Her bone age was 13.4 ...

Last Updated: 30 Jan 2008

Go To URL
Apoptosis and P53, Bcl-2 and Bax gene expression in parathyroid glands of patients with hyperparathyroidism.
 

Author(s): Béla Szende, Parvaneh Farid, Gyula Végso, Ferenc Perner, László Kopper

Journal: Pathol. Oncol. Res.. 2004 ;10(2):98-103.

 

Altogether 107 patients were operated on at the Department of Transplantation and Surgery of Semmelweis University in the past four years, for clinical symptoms of hyperparathyroidism. Clinical and laboratory data of the patients supported the diagnosis of primary or secondary hyperparathyroidism. ...

Last Updated: 9 Jun 2004

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Hyperparathyroidism 2" returned 1 free, full-text review articles on human participants. First 3 results:

Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
 

Author(s): Nobuo Nagano, Edward F Nemeth

Journal: J. Pharmacol. Sci.. 2005 Mar;97(3):355-60.

 

Circulating levels of calcium ion (Ca(2+)) are maintained within a narrow physiological range mainly by the action of parathyroid hormone (PTH) secreted from parathyroid cells. Parathyroid cells can sense small fluctuations in plasma Ca(2+) levels by virtue of a cell surface Ca(2+) ...

Last Updated: 23 Mar 2005

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
 

Status: Recruiting

Condition Summary: Hyperparathyroidism

 

Last Updated: 4 Sep 2013

Go to URL

Last Updated: 18 Dec 2013

Go to URL